Boston Scientific agrees to a $415 million deal to add Bayer's interventional business to its peripheral interventions unit, adding thrombectomy and atherectomy devices to its portfolio.
Boston Scientific (NYSE:BSX) said it agreed to acquire Bayer AG's interventional unit for $415 million, in a move to significantly bolster its own $200 million peripheral interventions business.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1jxA30M
Cap comentari:
Publica un comentari a l'entrada